Early Access

Rareg supports stakeholders involved in Early Access and Expanded Access programs, providing strategic, regulatory, and operational expertise to facilitate patient access to innovative therapies in compliance with applicable national regulations.

How We Support Early Access Programs

  • Evaluation of feasibility of early access programs for the specific disease area, indication, product
  • Expert support to companies for regulatory and logistic aspects of setting up early access programs
  • Support to clinicians/scientific societies/patient associations for the preparation and follow-up of requests:
    • for inclusion in the list of reimbursed products according to Law 648/96
    • for named patient reimbursement according to Law 326/2003 (Fondo AIFA 5%)
    • for compassionate use/expanded access according to DM 7th September 2017